Search results for "Venous thromboembolism."

showing 10 items of 136 documents

Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

2018

After acute proximal deep vein thrombosis (DVT) the thrombotic mass decreases, especially during the first months of anticoagulation. The persistence of residual vein obstruction (RVO) may predict future recurrence in patients with cancer-associated DVT. We aimed to evaluate the proportion of patients with RVO after an episode of cancer associated isolated distal DVT (IDDVT), to identify variables associated with RVO, and to provide initial evidence of its association with recurrent VTE. We performed a post-hoc analysis of a multicenter cohort study of patients with isolated cancer-associated acute IDDVT. We included patients who underwent a control ultrasonography at the end of the anticoa…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep vein030204 cardiovascular system & hematologyCompression ultrasound; Distal deep vein thrombosis; Recurrence; Residual vein obstruction; Venous thromboembolism; Hematology; Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsInternal medicineNeoplasmsmedicineHumansIn patientDistal deep vein thrombosiAgedUltrasonographyVenous ThrombosisHematologybusiness.industryRisk FactorAnticoagulantAnticoagulantCancerAnticoagulantsHematologyVenous ThromboembolismCompression ultrasoundMiddle Agedmedicine.diseaseThrombosisSurgeryDiscontinuationmedicine.anatomical_structureDistal deep vein thrombosis030220 oncology & carcinogenesisResidual vein obstructionAcute DiseaseNeoplasmFemalebusinessCardiology and Cardiovascular MedicineHumanCohort studyJournal of thrombosis and thrombolysis
researchProduct

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with…

2018

Summary Venous thromboembolism (VTE)‐BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice‐based conditions. We calculated the prognostic indices of VTE‐BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all‐cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at‐risk time was 190 days (interquartile range 106–360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3–5·2] and the treatment‐adjusted HR was 2·3 (95% CI 1·1–4·5) for VTE‐BLEED high (versus low) risk patients: the correspondi…

AdultMalemedicine.medical_specialtyvenous thromboembolismHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicinemedicineanticoagulation therapy; bleeding; prediction; rivaroxaban; venous thromboembolism; HematologyHumans030212 general & internal medicinecardiovascular diseasesProspective StudiesAdverse effectrivaroxabanRivaroxabananticoagulation therapybusiness.industryIncidence (epidemiology)Platelets Haemostasis and ThrombosisHazard ratioHematologypredictionBleedMiddle Agedequipment and suppliesbleedingConfidence intervalddc:Survival RateCohortFemalebusinessmedicine.drugResearch Paper
researchProduct

Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosi…

2012

Abstract Although below-knee compression elastic stockings (CES) are effective for the prevention of the postthrombotic syndrome (PTS), a substantial number of patients with deep venous thrombosis still develop PTS. In the present open-label, randomized clinical trial, we compared thigh-length with below-knee CES for the prevention of PTS. A total of 267 patients with the first episode of proximal deep venous thrombosis were randomized to wear either thigh-length or below-knee CES for 2 years. After 3, 6, 12, 18, 24, and 36 months, they were assessed for PTS manifestations according to the Villalta scale. PTS developed in 44 (32.6%) of the 135 patients randomized to thigh-length CES and in …

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyTime FactorsImmunologyThighbehavioral disciplines and activitiesBiochemistryPostthrombotic SyndromeSettore MED/15 - Malattie Del Sanguelaw.inventionPOST-THROMBOTIC SYNDROMEYoung AdultRandomized controlled triallawmedicineHumansKneeAgedAged 80 and overVenous ThrombosisFirst episodeVENOUS THROMBOEMBOLISMbusiness.industryPruritusHazard ratioCell BiologyHematologyMiddle Agedmusculoskeletal systemmedicine.diseaseThrombosishumanitiesConfidence intervalDiscontinuationSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureThighErythemaPatient ComplianceFemalevenous thrombosisbusinessStockings CompressionFollow-Up StudiesBlood
researchProduct

Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline

2016

AdultVenous ThrombosisParenteral Nutritionmedicine.medical_specialtyNutrition and DieteticsAdult patientsbusiness.industryAnticoagulantsVenous ThromboembolismGuideline030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinemedicine.diseaseThrombosis03 medical and health sciencesVenous thrombosis0302 clinical medicineParenteral nutritionmedicineHumans030211 gastroenterology & hepatologyParenteral Nutrition HomeIntensive care medicinebusinessVenous thromboembolism
researchProduct

Topical Issues in Venous Thromboembolism

2010

Despite clear guidelines and the availability of effective treatments, venous thromboembolism (VTE) remains relatively common, particularly in the hospital setting. This paper reviews topical issues in VTE, in terms of treatments, data and guidelines. Existing anticoagulants have several limitations. Bleeding risk is a concern with all anticoagulants. Vitamin K antagonists are the mainstay of oral anticoagulant therapy, but they are limited by the need for frequent monitoring. Unfractionated heparin (UFH) is limited by an inconvenient route of administration (continuous intravenous infusion) and a higher risk of heparin-induced thrombocytopenia and bleeding compared with low molecular weigh…

Adultmedicine.medical_specialtyBlood Loss SurgicalVenographyFondaparinuxRoute of administrationPharmacotherapymedicineHumansPharmacology (medical)DosingChildIntensive care medicineSocieties Medicalmedicine.diagnostic_testbusiness.industryAnticoagulantsVenous ThromboembolismHeparinmedicine.diseaseUnited StatesClinical trialVenous thrombosisClinical AlarmsPractice Guidelines as TopicDrug Monitoringbusinessmedicine.drugDrugs
researchProduct

Evaluation of the Stratus® CS Acute Care™ D-dimer assay (DDMR) using the Stratus® CS STAT Fluorometric Analyzer: A prospective multisite study for ex…

2012

Abstract Background D-dimer testing is an integral part of the diagnostic algorithm in excluding patients with venous thromboembolism. In this study, we prospectively evaluated the Stratus DDMR D-dimer test in patients suspected of pulmonary embolism (PE) and deep vein thrombosis (DVT). Methods Patients suspected of venous thromboembolism were prospectively enrolled at four different clinical sites, with sodium citrate and lithium heparin plasma was tested using the DDMR D-dimer test on the Stratus CS analyzer. Results 1,012 patients were enrolled for analysis, with 85/603 (14.1%) patients with PE and 80/443 (18.1%) with DVT, and four of the patients (0.4%) with PE and DVT. For the samples …

Adultmedicine.medical_specialtyDeep veinGastroenterologyD-dimer assayFibrin Fibrinogen Degradation ProductsYoung AdultInternal medicineAcute caremedicineHumansFluorometryProspective Studiescardiovascular diseasesProspective cohort studyAgedAged 80 and overImmunoassayVenous Thrombosisbusiness.industryHematologyHeparinMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structurePulmonary EmbolismbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct

Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in T…

2019

Cardiovascular and especially thrombotic diseases remain a major cause of morbidity and mortality worldwide. In past years, significant improvements in understanding disease processes, risk assessment, and prediction of clinical outcome in the field of thrombosis and haemostasis have been made by using large-scale biodatabases. These important research resources enable a comprehensive research approach by integrating clinical, environmental, genomic, and molecular information. Cutting edge, high throughput technologies open new data dimensions for clinical large-scale investigations. Joining multiple information levels from several pathophysiological pathways in contrast to a single marker …

Blood Plateletsmedicine.medical_specialtyDatabases Factualbusiness.industryThrombosisHematologyDisease030204 cardiovascular system & hematologyDisease pathogenesisPrecision medicine03 medical and health sciences0302 clinical medicineCoagulationmedicineHumansPlateletThrombotic diseasePrecision MedicineRisk assessmentIntensive care medicinebusinessBlood CoagulationVenous thromboembolismBiomarkers030215 immunologyHämostaseologie
researchProduct

Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark.

2020

Cerebral veinsmedicine.medical_specialtybusiness.industrymedicine.drug_classSplanchnic Circulation10031 Clinic for Angiology2720 HematologyAnticoagulantanticoagulantvenous thromboembolism610 Medicine & healthHematologyCerebral vein thrombosisbleedingcerebral veinsplanchnic circulationsInternal medicineCardiologyCommentaryMedicineDiseases of the blood and blood-forming organsRC633-647.5businessSplanchnicVenous thromboembolismResearch and practice in thrombosis and haemostasis
researchProduct

Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women’s Health of the Society of Thrombosis and Hae…

2016

Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. However, because there is a lack of adequate study data, management strategies for pregnancy-associated VTE must be deduced from observational stu-dies and extrapolated from recommendations for non-pregnant patients. In this review, the members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH) have summarised the evidence that is currently available in the literature to provide a practical approach for treating pregnancy-associated VTE. Because heparins do not cross the placenta, weight-adjusted therapeutic-dose low molecular weight heparin …

Diagnostic Imagingmedicine.medical_specialtyConsensusmedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinFibrin Fibrinogen Degradation ProductsPredictive Value of TestsPregnancyRisk FactorsHumansMedicinecardiovascular diseasesDosingIntensive care medicineVenous ThrombosisPregnancybusiness.industryWarfarinReproducibility of ResultsVenous Thromboembolismmedicine.diseasePulmonary embolismVenous thrombosisFemaleObservational studyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessBiomarkersPostpartum periodmedicine.drugVasa
researchProduct